KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Treasury Shares (2018 - 2025)

Esperion Therapeutics (ESPR) has disclosed Treasury Shares for 6 consecutive years, with $55.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Treasury Shares changed 0.0% year-over-year to $55.0 million, compared with a TTM value of $55.0 million through Dec 2025, changed 0.0%, and an annual FY2025 reading of $55.0 million, changed 0.0% over the prior year.
  • Treasury Shares was $2.0 million for Q4 2025 at Esperion Therapeutics, roughly flat from $2.0 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $2.0 million in Q1 2021 and bottomed at $2.0 million in Q1 2021.
  • Average Treasury Shares over 5 years is $2.0 million, with a median of $2.0 million recorded in 2021.
  • Peak annual rise in Treasury Shares hit 0.0% in 2021, while the deepest fall reached 0.0% in 2021.
  • Year by year, Treasury Shares stood at $55.0 million in 2021, then changed by 0.0% to $55.0 million in 2022, then changed by 0.0% to $55.0 million in 2023, then changed by 0.0% to $55.0 million in 2024, then changed by 0.0% to $55.0 million in 2025.
  • Business Quant data shows Treasury Shares for ESPR at $55.0 million in Q4 2025, $55.0 million in Q3 2025, and $55.0 million in Q2 2025.